Metavone’s Isoflavone Drug Technology (IDT) Compounds:
Targeted to be taken orally
Metavone’s isoflavone compounds by screening suggest that more than 90% have the potential to pass through the intestine and enter the bloodstream. These results indicate that any drug developed from the compounds could be administered orally with a tablet, rather than via invasive procedures such as an intravenous injection.
Low toxicity potential
Safety analysis performed on Metavone’s isoflavone compounds, show that 135 of the 138 isoflavone compounds have a low likelihood of potential adverse reaction. The three compounds that showed potential mutagenic or tumourigenic activity will be either further examined to confirm this activity or excluded from further research.
Ability to cross the blood-brain barrier
One of the biggest challenges in treating neurological conditions is that the brain is separated from the bloodstream by the blood-brain barrier. Large molecules cannot pass through this barrier, preventing the brain from becoming infected but making it difficult to treat when things go wrong. Initial screening suggests that more than 80% of Metavone’s isoflavone compounds have demonstrated the potential to cross from the bloodstream into the brain. This points to the opportunity to use these compounds for the treatment of brain diseases, including dementia.
Targeted to be used against drug-resistant cancers
All Metavone’s compounds have been screened to ensure they cannot combine with a substance known as p-glycoprotein, which actively prevents drugs from entering cells. In this screening, none of Metavone’s isoflavones compounds combine with p-glycoprotein, and approximately one quarter of the compounds have been found to potentially inhibit it. This opens up an additional opportunity to use the Company’s isoflavone compounds in combination with existing cancer treatments against cancers displaying multidrug resistance. This resistance is particularly prevalent in ovarian cancer.